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Abstract
Background: In clinical trials, immunopotentiating reconstituted influenza virosomes (IRIVs) have shown great
potential as a versatile antigen delivery platform for synthetic peptides derived from Plasmodium falciparum
antigens. This study describes the immunogenicity of a virosomally-formulated recombinant fusion protein
comprising domains of the two malaria vaccine candidate antigens MSP3 and GLURP.
Methods: The highly purified recombinant protein GMZ2 was coupled to phosphatidylethanolamine and the
conjugates incorporated into the membrane of IRIVs. The immunogenicity of this adjuvant-free virosomal
formulation was compared to GMZ2 formulated with the adjuvants Montanide ISA 720 and Alum in three mouse
strains with different genetic backgrounds.
Results: Intramuscular injections of all three candidate vaccine formulations induced GMZ2-specific antibody
responses in all mice tested. In general, the humoral immune response in outbred NMRI mice was stronger
than that in inbred BALB/c and C57BL/6 mice. ELISA with the recombinant antigens demonstrated
immunodominance of the GLURP component over the MSP3 component. However, compared to the Al(OH)3-
adjuvanted formulation the two other formulations elicited in NMRI mice a larger proportion of anti-MSP3
antibodies. Analyses of the induced GMZ2-specific IgG subclass profiles showed for all three formulations a
predominance of the IgG1 isotype. Immune sera against all three formulations exhibited cross-reactivity with in
vitro cultivated blood-stage parasites. Immunofluorescence and immunoblot competition experiments showed
that both components of the hybrid protein induced IgG cross-reactive with the corresponding native
proteins.
Conclusion: A virosomal formulation of the chimeric protein GMZ2 induced P. falciparum blood stage parasite
cross-reactive IgG responses specific for both MSP3 and GLURP. GMZ2 thus represents a candidate component
suitable for inclusion into a multi-valent virosomal malaria vaccine and influenza virosomes represent a versatile
antigen delivery system suitable for adjuvant-free immunization with recombinant proteins.
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The currently available strategies for malaria control rely
on destruction of malaria parasites with drugs and the
anopheline vectors with insecticides [1]. This combined
approach proved remarkably effective in Europe and
North America, whereas malaria continues to represent
a huge burden in sub-Saharan Africa, Asia and South
and Central America mainly due to drug-resistant para-
sites and insecticide resistant vectors [2]. A malaria vac-
cine is anticipated to be the most effective public health
tool for changing this situation.
The expected outcome of modern malaria vaccine
development has shifted from protecting against the
parasite to surviving with the parasite, but without
experiencing the noxious effects it can cause. Asexual
blood-stage vaccines are aimed to primarily protect
against the clinical symptoms of severe and mild malaria
disease, and not against the infection, on the assumption
that inhibition of parasite invasion cycles will lead to
reduced parasite burden and decreased morbidity and
mortality [3]. Merozoite surface proteins are, therefore,
a major focus of research for blood-stage vaccines. One
of the leading candidates for an anti-falciparum vaccine
is GMZ2, a fusion protein consisting of the N-terminal
portion of the Glutamate Rich Protein (GLURP) geneti-
cally fused to a C-terminal fragment of Merozoite Sur-
face Protein 3 (MSP3) [4]. Data supporting MSP3 and
GLURP as vaccine candidates rely on in vitro and in
vivo preclinical models and on immuno-epidemiological
studies demonstrating a statistically significant associa-
tion between protection from clinical malaria and anti-
gen recognition by exposed individuals [5-13].
Development of an effective vaccine against blood-
stage infection will depend not only on antigen quality,
but also on the choice of an optimal antigen delivery
platform. In general, research on subunit vaccines
focused mainly on antigen discovery whereas the
method for inducing appropriate immune responses
against these antigens has received less attention [14].
The selection of immunopotentiators, however, can have
critical effects on safety, stability, immunogenicity and,
consequently, efficacy of a vaccine [15]. The paucity of
delivery systems is apparent by the fact that aluminium
salts identified as immunopotentiators more than 70
years ago have remained the most common type of
adjuvant licensed worldwide. Alum is regarded as safe
and as a stimulator of Th2 immunity and is, therefore,
used as a standard to compare to other adjuvants [16].
The need for more effective antigen delivery systems for
use in vaccines against malaria is made clear by the
poor responses to synthetic and recombinant malarial
antigens seen with the use of Alum [17-20]. Two such
antigen delivery systems are Montanide ISA 720 and
immunopotentiating reconstituted influenza virosomes
(IRIV). The experimental Montanide ISA 720 adjuvant
forms water-in-oil droplets intended to give a slow
release of antigens at the injection site [21]. Montanide
ISA 720 based formulations have been shown to elicit
high antibody titres in several animal species [22], and
have also been investigated in malaria vaccine trials
[23-26]. IRIVs are spherical, unilamellar vesicles, pre-
pared by detergent removal from a mixture of natural
and synthetic phospholipids and influenza surface glyco-
proteins. The haemagglutinin membrane glycoprotein of
the influenza virus is a fusion-inducing component,
which facilitates antigen delivery to immunocompetent
cells. IRIVs represent a universal antigen delivery system
for multicomponent subunit vaccines, as antigens can
be either coupled to their surface to elicit CD4 T cell
and antibody responses or encapsulated in their lumen
to elicit CD8 T cell responses. Experience with two
licensed vaccines based on virosomes (Inflexal
® Va n d
Epaxal
®)a sw e l la sc l i n i c a lt r i a l sw i t hv i r o s o m a l l y - f o r -
mulated malaria vaccine candidates [27,28] have shown
that IRIV-based formulations are immunogenic even in
children and infants, and display a very good safety pro-
file [29,30].
In the present report, a hybrid MSP3/GLURP recom-
b i n a n tp r o t e i n( n a m e dG M Z 2 )w a sc o u p l e dt ot h es u r -
face of IRIVs. The immunogenicity of this formulation
was compared to vaccine candidate preparations of
GMZ2 in Montanide ISA 720 and Alum in three differ-
ent mouse strains.
Methods
GMZ2 hybrid recombinant protein production and
candidate vaccine formulations
Production and purification of the recombinant GMZ2
hybrid molecule, a fusion protein containing the regions
GLURP27-500 (GLURP-R0) and MSP3212-380 (MSP3 C-
terminal), has been described in detail elsewhere [4]. To
prepare GMZ2-IRIV, 5 nmol of the purified hybrid pro-
tein was activated by incubation with 100 nmol of sulfo-
succinimidyl 4-[N-maleimidomethyl] cyclohexane-1-
carboxylate (Sulfo-SMCC; Thermo Scientific) for 1 h at
room temperature. This was followed by conjugation to
1, 2-dipalmitoyl-sn-glycero-3-phosphothioethanol
(Avanti Polar Lipids) for 4 h at room temperature, prior
to incorporation into influenza virosomes, as described
in [31]. Virosomes were aliquoted and stored at 4°C.
The mixture of GMZ2 with Alum (Al(OH)3) was pre-
pared as follows: 0.23 mg of GMZ2 protein was diluted
in 3.7 mL of PBS pH 7.4, and 0.93 mL of Alum suspen-
sion (Imject Alum, 10 mg/mL; Thermo Scientific) was
added dropwise under continuous mixing. The solution
was aliquoted and stored at 4°C. The mixture of GMZ2
with Montanide was prepared as follows: 0.05 mg of
GMZ2 protein was diluted in 0.38 mL of PBS pH 7.4,
Tamborrini et al. Malaria Journal 2011, 10:359
http://www.malariajournal.com/content/10/1/359
Page 2 of 11and 0.5 mL of Montanide ISA 720 solution (Seppic SA,
France) was added dropwise under continuous mixing.
This was followed by vigorous pushing through a syr-
inge needle (18 G 1.5”,1 . 2×4 0m m )f o r2 5t i m e s .T h i s
solution was used within 24 h after preparation.
Mouse immunogenicity studies
BALB/c, C57BL/6, and NMRI mice (five animals/group)
purchased by Charles River were pre-immunized intra-
muscularly with 0.1 mL of inactivated influenza virus
(Influenza A/Singapore/6/86 (H1N1), 1 μg of haemagglu-
tinin; Berna Biotech, Switzerland). Induction of influenza
antigen-specific CD4 T-cells can provide T-cell help for
B cells that recognize the foreign malaria antigen on the
surface of IRIVs and thus enhance the immune response
to the GMZ2 protein. Three- and six weeks later, mice
were immunized with a dose of 5 μg GMZ2 administered
either in association with Alum, Montanide ISA 720, or
IRIVs (Figure 1). Approval for animal experimentation
has been obtained from the responsible authorities and
a l la n i m a lm a n i p u l a t i o n shave been performed under
controlled laboratory conditions by specifically qualified
personnel in strict accordance with the Rules and Regula-
tions for the Protection of Animal Rights laid down by
the Swiss Bundesamt für Veterinärwesen.
ELISA
ELISA MaxiSorp microtitre plates (Nunc, Dr. Grogg,
Stetten-Deiswill, Switzerlan d )w e r ec o a t e da t4 ° Co v e r -
night with 1 μg/mL GMZ2 in carbonate buffer (0.05 M;
pH 9.4) or with the individual GLURP and MSP3
recombinant proteins. Production and purification of
the GLURP and MSP3 proteins has been described
elsewhere [4]. Wells were then blocked with 5% milk
powder in PBS pH 7.4 for 1 h at 37°C followed by three
washings with PBS containing 0.05% Tween-20. Plates
were incubated with two-fold serial dilutions of sera
starting with 1:50 in PBS pH 7.4 containing 0.05%
Tween-20 and 0.5% milk powder for 2 h at 37°C. After
washing, the plates were incubated with horseradish-
peroxidase conjugated goat anti-mouse IgG antibodies
(BD; 1:2000 in PBS containing 0.05% Tween-20 and
0.5% milk powder) for 1 h at 37°C and then washed.
One OPD tablet (Sigma, Switzerland) was dissolved in
citrate-buffer and 0.04% H2O2 (v/v) was added followed
by an incubation at room temperature in the dark. After
5 min the reaction was stopped by addition of sulphoric
acid (Merck, Darmstadt, Germany) to reach a final con-
centration of 0.5 M. The optical density (OD) of the
reaction product was recorded at 492 nm using a micro-
plate reader (SpectraMax plus, Bucher Biotech, Basel,
Switzerland). Titration curves were registered using
Softmax PRO software. Endpoint titres were calculated
by comparing the ELISA OD of the test serum with the
ELISA OD of PBS. Endpoint titre is the last serum dilu-
tion where the OD of the test sera > 2 × OD492 of the
negative control (PBS).
The anti-GMZ2, GLURP and MSP3 IgG subclasses
were determined by ELISA as described above. HRP-
conjugated goat anti-mouse IgG1, IgG2a, IgG2b and
I g G 3( C a l t a g ,U K )w e r eu s e da ta1 : 2 0 0 0d i l u t i o ni n
PBS. The results are expressed as mean OD492 + S.D.
Indirect immunofluorescence assay (IFA)
Plasmodium falciparum strain 3D7 was cultured essen-
tially as described previously [32]. Synchronized P.
Figure 1 GMZ2 formulations, immunization protocol and analysis schedule.
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volumes of a solution containing 4% (v/v) paraformalde-
hyde and 0.1% (v/v) Triton X-100. Droplets of 40 μLo f
cell suspension were added to each well of a diagnostic
microscope slide (Flow Laboratories, Baar, Switzerland)
and incubated for 30 min at room temperature. Cells
were blocked with blocking solution containing 100 mg/
mL fatty acid-free bovine serum albumin in PBS pH 7.4.
Immunostaining was performed by incubating the wells
with 25 μL of an appropriate serum dilution in blocking
solution in a humid chamber for 1 h at room tempera-
ture. In competition experiments primary antibodies
were pre-incubated for 30 min with recombinant com-
petitors at a concentration of 10 μg/mL. After five
washes with blocking solution, 25 μLo f5μg/mL indo-
carbocyanine dye-conjugated affinity-pure F(ab’)2 frag-
ment goat anti-mouse IgG heavy-chain antibodies
(Jackson ImmunoResearch Laboratories, West Grove,
Pa.), diluted in blocking solution were added to the
wells and incubated for 1 h at room temperature.
Finally, the wells were washed five times, mounted with
ProLong
® Gold antifade reagent with DAPI (Invitrogen)
and covered with a coverslip. Antibody binding and
DNA staining were assessed by fluorescence microscopy.
Sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) and immunoblotting
Parasite lysates were prepared by saponin lysis of P. fal-
ciparum 3D7-infected erythrocytes. Cultured parasites
were collected at the schizont stage and washed three
times with RPMI medium. Pelleted infected red blood
cells were lysed by mixing with a large volume (adjusted
to 5% haematocrit) of 0.015% (w/v) saponin in PBS and
incubated on ice for 20 min. Finally, the pelleted para-
sites were resuspended in PBS and stored at -80°C until
further use.
A total of 50 μl of parasite lysate was solubilized in an
equal volume of 2× loading buffer (1.7 mL of 0.5 M
Tris-HCl [pH 6.8], 2 mL of glycerol, 4.5 mL of 10% [w/
v] sodium dodecyl sulfate, 1 ml of b-mercaptoethanol,
0.8 ml of 0.3%, w/v bromophenol blue) and heated to
95°C for 10 min. Proteins were separated on an SDS-
PAGE minigel and electrophoretically transferred to a
nitrocellulose filter by semidry blotting. Blots were
blocked with PBS containing 5% milk powder and 0.1%
Tween 20 overnight at 4°C. The filter was cut into strips
and incubated with appropriate dilutions of immune
serum in blocking buffer for 2 h at room temperature.
In competition experiments primary antibodies were
pre-incubated for 30 min with recombinant competitors
at a concentration of 1 μg/mL. After several washing
steps, filter strips were incubated with goat anti-mouse
IgG horseradish peroxidase conjugated Ig (0.1 μg/mL;
Bio-Rad Laboratories, Hercules, Calif.) for 1 h. Blots
were developed using the ECL (Pierce) system according
to manufacturer’s instructions.
Results
Development of anti-GMZ2 IgG responses in mice
In order to examine whether an adjuvant-free IRIV formu-
lation of the recombinant hybrid protein GMZ2 elicits P.
falciparum cross-reactive antibody responses, highly puri-
fied GMZ2 was chemically coupled to phosphatidylethano-
lamine and then attached to the surface of IRIVs. Since a
vaccine needs to be immunogenic in genetically diverse
populations, outbred and inbred mice were immunized to
investigate antibody responses to GMZ2 and to evaluate
the effects of immunogenetic differences. Outbred (NMRI)
and inbred (BALB/c and C57BL/6) mice were immunized
two times with a dose of 5 μg of GMZ2 either coupled to
IRIVs or as adjuvanted formulation in combination with
either Al(OH)3 or Montanide ISA 720. Sera collected 3
weeks after the second immunization were assessed for IgG
antibody titres specific for GMZ2 and its individual GLURP
and MSP3 components by ELISA (Figure 2). Significant dif-
ferences in IgG antibody responses were found between the
mouse strains. In outbred NMRI mice, non-adjuvanted
GMZ2 coupled to IRIVs elicited comparable anti-GMZ2-
specific IgG responses as the adjuvanted formulations (Fig-
ure 2). In the inbred mouse strains (BALB/c and C57BL/6),
GMZ2 adjuvanted with Montanide ISA 720 was generally
more immunogenic than GMZ2 on IRIVs or in Al(OH)3.
In all immunization groups both anti-MSP3 and anti-
GLURP IgG were elicited by GMZ2 immunization. In gen-
eral the anti-GLURP ELISA titres were higher than anti-
MSP3 titres. Compared to the Al(OH)3-adjuvanted formu-
lation the two other formulations showed increased anti-
MSP3-specifc titres in NMRI mice. No GMZ2-specific IgG
responses were found in pre-immune sera.
Since outbred mice represent better the genetic varia-
bility of humans and showed the highest ELISA titres of
all three formulations, GMZ2-specific IgG subclass
levels were only assessed in NMRI mice (Figure 3). All
three formulations elicited predominantly IgG1. While
the Montanide ISA 720 formulation elicited significant
anti-GMZ2, MSP3 and GLURP IgG2a levels, IgG2a
levels were comparatively low for the Alum preparation.
GMZ2 coupled to IRIVs also induced substantial anti-
GMZ2 and GLURP IgG2a levels. Anti-GMZ2 IgG2b and
IgG3 levels were low for all three formulations.
Induction of parasite cross-reactive IgG antibodies
Induction of P. falciparum blood stage cross-reactive IgG
upon immunization with GMZ2 was analyzed by immu-
nofluorescence analysis (IFA) and immunoblotting with
sera from the immunized NMRI mice, since these mice
showed the highest ELISA titres of all three formulations.
All animals developed a parasite cross-reactive IgG
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cited generally the highest mean IFA (Figure 4a) and Wes-
tern blot (Figure 4b, c) titres. In contrast to the ELISA
results, in Western blot analyses with parasite lysates the
GLURP immunoblot IgG levels were lower than MSP3
specific IgG titres for all formulations (Figure 4b, c). How-
ever, this discrepancy could be related to different expres-
sion levels of the two individual malaria proteins. In
competition IFA, staining of blood stage parasites by anti-
GMZ2 antiserum was completely blocked by recombinant
GMZ2, but not with the individual GLURP or MSP3
recombinant proteins (Figure 5). Residual GLURP and
MSP3 specific IFA staining patterns were similar. Western
blot competition experiments allowed to assess the MSP3
and GLURP cross-reactive antibody responses. P. falci-
parum-derived proteins were stained with anti-GMZ2
mouse antiserum pre-incubated with or without the
recombinant competitor proteins GMZ2, MSP3 or
GLURP (Figure 6). Competition with recombinant MSP3
did not abolish staining of the high molecular weight para-
site-derived GLURP [4]. Competition with recombinant
GLURP left a triple band unchanged, which is characteris-
tic for processed MSP3 [33]. None of the pre-immune
sera was positive in IFA or Western blot.
Discussion
The development of protein subunit vaccines is often
hampered by limited intrinsic immunostimulatory prop-
erties and the lack of cross-reactivity of elicited
antibodies with the native target antigens. In an attempt
to overcome both problems, the immunogenicity of a
non adjuvanted virosomal formulation of the GMZ2
recombinant antigen was systematically evaluated in
comparison to GMZ2 adjuvanted in Al(OH)3 and Mon-
tanide ISA 720 in outbred and inbred mice. The GMZ2
candidate malaria vaccine antigen is a chimeric protein
consisting of the conserved N-terminal portion of
GLURP genetically fused to the conserved C-terminal
portion of MSP3 [4]. All GMZ2 vaccine formulations
induced antibody responses in all mouse strains tested.
IgG titres were higher in outbred NMRI mice than in
the two inbred mice strains. Previously tested non-adju-
vanted GMZ2 formulations have elicited either no or
only very weak antibody responses [34]. However, in the
present study anti-GMZ2-specific IgG responses elicited
by the non-adjuvanted GMZ2 coupled to IRIVs were
comparable to those found for adjuvanted formulations.
Compared to the Alum adjuvanted formulation the viro-
somal preparation increased the proportion of MSP3-
specifc IgG antibodies, thereby balancing the immuno-
genicity between the two individual domains. This find-
ing is potentially important as previous studies in
humans [35], Saimiri monkeys [36] and mice [4] have
consistently demonstrated that the GLURP domain of
GMZ2 is more immunogenic than the MSP3 domain.
The reason for this increase in immunogenicity of the
MSP3 domain is not known, but it may be speculated
that the display of GMZ2 on the surface of the
Figure 2 Development of anti-GMZ2, anti-GLURP and anti-MSP3 total IgG responses in three mouse strains upon immunization with
differentially-formulated GMZ2. Shown are ELISA mean endpoint titres (+ S. D.) of individual immunization groups.
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Page 5 of 11Figure 3 Determination of the IgG subclass profiles by ELISA using GMZ2 and the individual proteins MSP3 and GLURP.R e s u l t sa r e
expressed as mean OD492 + S.D. Sera from five NMRI mice in each group collected after the third immunization were tested individually.
Shown are results of a single dilution (1:6400 for sera of mice immunized with Montanide ISA 702 adjuvanted GMZ2 (a), 1:800 for sera of mice
immunized either with IRIV (b) or Alum (c) formulated GMZ2.
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Page 6 of 11Figure 4 Parasite cross-reactivity of anti-GMZ2 IgG responses. Immune sera of differentially-formulated NMRI mice were tested for parasite
binding in IFA (a) with in vitro cultured P. falciparum blood stage parasites and Western blot analysis (b, c) with parasite lysate. Shown are
endpoint titres observed with sera of individual animals, the horizontal lines are representing the geometric mean.
Figure 5 Competition immunofluorescence staining of in vitro cultivated P. falciparum schizonts with recombinant GMZ2, MSP3 or
GLURP. Parasites were stained with anti-GMZ2 immune serum of a NMRI mouse pre-incubated without or with recombinant competitors.
Immune serum was used at a dilution of 1:1000 and competitors at a concentration of 10 μg/mL. Nuclei were visualized using DAPI staining.
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MSP3.
Several parameters may influence IgG subclass profiles
of antibody responses towards proteins, including
antigen dosage, use of adjuvants or delivery platforms,
and the intrinsic immunogenicity of the protein itself
[37]. All GMZ2 vaccine formulations tested here
induced predominantly subclass IgG1 responses in mice.
Figure 6 Competition Western blot analysis with lysates from P. falciparum blood stage parasites and recombinant GMZ2, MSP3 or
GLURP. Total lysates of in vitro cultivated parasites were separated by SDS-PAGE under reducing conditions and blotted onto a nitrocellulose
membrane. Serum of a NMRI mouse immunized with IRIV-formulated GMZ2 was pre-incubated with or without recombinant competitor protein
and subsequently added to cut strips. Immune serum was used at a dilution of 1:2000 and competitors at a concentration of 1 μg/mL.
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lators can influence the sub-class profile and it was
recently demonstrated that the addition of the TLR4
agonist GLA to oil-in-water or Al(OH)3 formulations of
GMZ2 effectively leads to an increase in vaccine-specific
cytophilic IgG2a and IgG2b antibodies and in particular
an increase in anti-MSP3-specific titres in CB6F1 mice
[34]. Thus, it may be speculated that the addition of
TLR agonists like GLA to the GMZ2 virosomal formula-
tion could enhance the overall IgG responses against
GMZ2 and modulate the IgG sub-class profile in mice.
Although, the use of potent adjuvants can increase
immunogenicity they can also be associated with
increased reactogenicity. In human clinical trials, injec-
tions of the water-in-oil emulsion Montanide ISA 720
alone were well tolerated [38]. However, some vaccine
formulations with Montanide ISA 720 were quite reac-
togenic [25,39-41] and issues regarding antigen stability
in long-term formulations were also reported [42].
Recently conducted safety and immunogenicity clinical
trials with aluminium hydroxide adjuvanted GMZ2 have
shown that the vaccine candidate is well tolerated, safe
and immunogenic in malaria-exposed and non-exposed
healthy adults [35,43] and young children [44]. Phase 2
efficacy trials are ongoing. It would be expected that a
non-adjuvanted virosomal formulation would be equally
safe since the influenza virosome antigen delivery plat-
form has already been commercialized and over 70 mil-
lion doses of virosome-based vaccines have been
administered in humans over the last 10 years, including
children and infants [29,30,45]. Moreover, the virosome
antigen delivery platform has already proven its suitabil-
ity for malaria vaccine design exhibiting an excellent
safety profile. Virosomes formulated with P. falciparum
peptides from both the pre-erythrocytic antigen CSP
and the blood-stage antigen AMA-1, have been success-
fully tested in clinical phase Ia and IIa trials [27,28]. A
phase Ib trial using this two-peptide formulation has
recently been finalized [45]. As an exploratory outcome,
the incidence rate of clinical malaria episodes in chil-
dren vaccinees was half the rate of the control children.
These promising results support the concept to develop
a multivalent virosomal malaria vaccine by incorporating
additional components, such as GMZ2, into the clini-
cally tested bivalent formulation.
Conclusions
Mouse immunogenicity data presented here, demon-
strate that a non-adjuvanted virosomal formulation of
the chimeric GMZ2 protein elicits high titres of parasite
cross-reactive antibodies. These results confirm that
virosomes represent a versatile antigen delivery platform
for multi-valent vaccines based on recombinant proteins,
synthetic peptides, and/or carbohydrates.
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